To develop compound that could slow the
progression of Alzheimer's disease
(Evotec and Roche)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Under the terms of the agreement, Roche will pay Evotec an upfront fee of $10 million. Evotec could receive further development and commercial milestone payments of up to $820 million as well as tiered double-digit royalties on sales. Roche will initiate studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, manufacturing and commercialization activities.
Evotec's compound (EVT 302) is a novel, potent inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals. Free radicals are known to cause oxidative stress which may contribute to pathogenesis of AD as demonstrated by the up-regulation of MAO-B expression in the brain of AD patients. For these reasons, the selective MAO-B inhibitor is targeted to treat AD symptoms and potentially slow disease progression.
The compound, which will be entering clinical studies in AD, was originally licensed from Roche to Evotec in 2006, and initially developed in another indication.
Continue to read: cisionwire.com
Resveratrol may prevent metabolic syndrome
Postnatal administration of resveratrol supplements could reduce the risk metabolic syndrome in offspring affected by impaired intrauterine growth, according to a new animal study performed by Canadian researchers. Read more: nutraingredients.com